How a Premier Single Source Platform Accelerates Biologic Drug Discovery and Innovation

2:45 PM - 3:05 PM (PDT), Tuesday, June 14, 2022

As a leading CRDMO, WuXi Biologics offers end-to-end solutions to enable global partners to discover, develop and manufacture biologics. Our full spectrum of cutting-edge technologies and highly efficient one-stop discovery services provide multiple integrated platforms from target identification to final lead candidate selection for antibody generation, protein engineering, lead selection, lead optimization, characterization and production. We bring industry-leading expertise and experience to help our clients to achieve their goals in finding monoclonal, bispecific, and multispecific antibody therapeutics, antibody drug conjugates, engineered cytokines and other protein therapeutics with desired functional properties. Our state-of-the-art facilities can meet any needs for high yield, high speed protein production at any scale using a variety of expression systems. Our approach to biologics discovery includes our efficient one-stop ADC platform, with services ranging from target selection, antibody generation, linker and payload conjugation, in vitro and in vivo biological and physiochemical characterization, and CMC development all the way to commercial manufacturing. In the past decade we have successfully enabled our clients to not only discover antibody lead candidate therapeutics starting from therapeutic concept but also to integrate discovery with CMC development to provide a highly efficient target to commercialization platform that leads to regulatory approval.